cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
== Clinical research == Although lipoic acid has been tested in clinical research for potential use as a therapy for various diseases, the studies have been of limited quality, with no conclusive evidence that it is warranted as a therapeutic, as of 2026. According to the American Cancer Society as of 2013, "there is no reliable scientific evidence at this time that lipoic acid prevents the development or spread of cancer". As of 2015, intravenously administered ALA is unapproved anywhere in the world except Germany for diabetic neuropathy, but has been proven reasonably safe and effective. As of 2012, there was no good evidence alpha lipoic acid helps people with mitochondrial disorders. A 2018 review found that ALA had a small effect to reduce body weight, but is not cost-effective as a dietary supplement. A 2025 study indicated a positive effect in a cellular model of Friedreich's ataxia.
Chanler, son of John Winthrop Chanler '47, husband of Amélie Rives Troubetzkoy Albert Payson Terhune (1893), author, dog breeder, journalist, Further Adventures of Lad Guy Wetmore Carryl (1895), humorist, Fables for the Frivolous Melville Henry Cane (1900), poet; winner of the Robert Frost Medal in 1971 Joyce Kilmer (1908), poet and author of Trees Randolph Bourne (1912), essayist and public intellectual Harold Lamb (1915), writer, screenwriter Gustav Davidson (1919), poet, secretary of the Poetry Society of America Paul Gallico* (1919), author of The Poseidon Adventure Louis Zukofsky (1922), co-founder and leading theorist of the Objectivist poets James Warner Bellah (1923), Western and pulp writer whose stories formed the basis of such John Ford classics as Fort Apache, She Wore a Yellow Ribbon, and Rio Grande. Corey Ford* (1923), humorist, The John Riddell Murder Case Henry Morton Robinson (1923), author of The Cardinal and A Skeleton Key to Finnegans Wake Cornell Woolrich (1923), mystery writer and author of Rear Window Clifford Dowdey (1925), author on the American Civil War Herman Wouk (1934), author of War and Remembrance and winner of the Pulitzer Prize for Fiction for The Caine Mutiny John Berryman (1936), winner of the Pulitzer Prize for Poetry Robert Paul Smith (1936), author of Where Did You Go? Out. What Did You Do? Nothing.
Dermatologists and estheticians offer professional skin care services. Consulting with a dermatologist is recommended for persistent or severe skin conditions. They can prescribe medications and customized skin care treatments. Some example procedures include chemical peels, laser resurfacing, photorejuvenation, photodynamic therapy, dermabrasion and microdermabrasion, collagen induction therapy, injectable fillers, botox injection, retinol therapy, ultrasonic skin treatment, and hair removal.
Sources: en.wikipedia.org
== Use as a lipid biomarker == Tetrahymanol has been found in many marine ciliates at relatively high concentrations, suggesting it may be a useful biomarker in the Earth's rock record. During diagenesis, the alcohol functional group is lost and tetrahymanol becomes gammacerane. Like other saturated triterpenoid skeletons, gammacerane is a highly stable molecule that can preserved in rocks on geological timescales. The oldest gammacerane biomarker was found in a rock 850 million years old. Based on microbial physiology studies, gammacerane was suggested as a potential biomarker for ocean stratification. When water columns stratify, anoxic conditions can form in the bottom waters. Ciliates living in these conditions must adapt to produce lipids that do not require molecular oxygen for their biosynthesis. A direct correlation between sterol availability and tetrahymanol synthesis in ciliates has been shown, leading to the hypothesis that gammacerane in sediments is a biomarker for ocean stratification. This hypothesis was later met with skepticism. While tetrahymanol had mostly been observed in ciliates, several bacteria were then shown to synthesize the lipid and many bacteria across multiple phyla had the gene for tetrahymanol synthase. This evidence has been used to question the potential of gammacerane as a biomarker for water column stratification. For instance, aerobic methanotrophic bacteria were shown to synthesize tetrahymanol. Thus it is not solely a response to anoxic environments.
At the October 1907 meeting of the American Roentgen Ray Society, Rome Vernon Wagner, an X-ray tube manufacturer, reported that he had begun carrying a photographic plate in his pocket and developing it every evening. This allowed him to determine how much radiation he had been exposed to. This was the forerunner of the film dosimeter. His efforts came too late, as he had already developed cancer and died six months after the conference. In the 1920s, the physical chemist John Eggert (1891-1973) played a key role in the introduction of film dosimetry for routine personal monitoring. Since then, it has been successively improved and, in particular, the evaluation technique has been automated since the 1960s. At the same time, Hermann Joseph Muller (1890-1967) discovered mutations as genetic consequences of X-rays, for which he was awarded the Nobel Prize in 1946. At the same time, the roentgen (R) was introduced as a unit for quantitative measurement of radiation exposure. A dosimeter for film is divided into multiple segments, each containing a light- or radiation-sensitive film surrounded by layers of copper and lead with varying thickness. The degree of radiation penetration determines whether the segment is not blackened or blackened to varying degrees. The absorbed radiation effect during the measurement time is summed up, and the radiation dose can be determined from the blackening. Guidelines for evaluation exist, with those for Germany being published in 1994 and last updated on December 8, 2003.
=== Biomedical applications === Quantitative proteomics has distinct applications in the medical field. Especially in the fields of drug and biomarker discovery. LC-MS/MS techniques have started to over take more traditional methods like the western blot and ELISA due to the cumbersome nature of labeling different and separating proteins using these methods and the more global analysis of protein quantification. Mass spectrometry methods are more sensitive to difference in protein structure like post-translational modification and thus can quantify differing modifications to proteins. Quantitative proteomics can circumvent these issues, only needing sequence information to be performed. It can be applied on a global proteome level, or on specifically isolating binding partners in pull-down or affinity purification experiments. Disadvantages, however, in sensitivity and analysis time must be kept in consideration.
Sources: en.wikipedia.org
=== Separation based on hydrophobicity (hydrophobic interaction chromatography) === HIC media is amphiphilic, with both hydrophobic and hydrophilic regions, allowing for the separation of proteins based on their surface hydrophobicity. Target proteins and their product aggregate species tend to have different hydrophobic properties and removing them via HIC further purifies the protein of interest. Additionally, the environment used typically employs less harsh denaturing conditions than other chromatography techniques, thus helping to preserve the protein of interest in its native and functional state. In pure water, the interactions between the resin and the hydrophobic regions of protein would be very weak, but this interaction is enhanced by applying a protein sample to HIC resin in a high ionic strength buffer. The ionic strength of the buffer is then reduced to elute proteins in order of decreasing hydrophobicity.
=== Ocean dumping of radioactive waste === Between 1969 and 1982, conditioned low- and intermediate-level radioactive waste was disposed of in the Atlantic Ocean at a depth of about 4,000 meters under the supervision of the Nuclear Energy Agency (NEA) of the Organization for Economic Cooperation and Development (OECD) in accordance with the provisions of the European Convention on the Prevention of Marine Pollution by Dumping of Waste of All Kinds (London Dumping Convention of June 11, 1974). This was carried out jointly by several European countries. Since 1993, international treaties have prohibited the dumping of radioactive waste in the oceans. For decades, this dumping of nuclear waste went largely unnoticed by the public until Greenpeace denounced it in the 1980s.
==== NOD-like receptors ==== Probably the most well-known receptors of peptidoglycan are the NOD-like receptors (NLRs), mainly NOD1 and NOD2. The NOD1 receptor is activated after iE-DAP (γ-d-glutamyl-meso-diaminopimelic acid) binding, while NOD2 recognizes MDP (muramyl dipeptide), by their LRR domains. Activation leads to self-oligomerization, resulting in activation of two signalling cascades. One triggers activation of NF-κB (through RIP2, TAK1 and IKK), second leads to MAPK signalling cascade. Activation of these pathways induces production of inflammatory cytokines and chemokines. NOD1 is expressed by diverse cell types, including myeloid phagocytes, epithelial cells and neurons. NOD2 is expressed in monocytes and macrophages, epithelial intestinal cells, Paneth cells, dendritic cells, osteoblasts, keratinocytes and other epithelial cell types. As cytosolic sensors, NOD1 and NOD2 must either detect bacteria that enter the cytosol, or peptidoglycan must be degraded to generate fragments that must be transported into the cytosol for these sensors to function. Recently, it was demonstrated that NLRP3 is activated by peptidoglycan, through a mechanism that is independent of NOD1 and NOD2. In macrophages, N-acetylglucosamine generated by peptidoglycan degradation was found to inhibit hexokinase activity and induce its release from the mitochondrial membrane. It promotes NLRP3 inflammasome activation through a mechanism triggered by increased mitochondrial membrane permeability. NLRP1 is also considered as a cytoplasmic sensor of peptidoglycan.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.